Jaguar health appoints biopharmaceutical industry veteran to execute company's in-licensing growth strategy in the areas of cancer and gi supportive care

Catherine miller collis was instrumental in bringing about jaguar's recent in-license agreement for fda-approved gelclair®, a protective gel for management of oral mucositis, a common, painful, and debilitating cancer treatment-related side effect san francisco, ca / accesswire / april 18, 2024 / jaguar health, inc. (nasdaq:jagx) ("jaguar") today announced that it has appointed biopharmaceutical industry veteran catherine miller collis to the role of senior vice president of growth strategy. "cathy collis was instrumental in bringing about the gelclair in-license agreement.
JAGX Ratings Summary
JAGX Quant Ranking